Please try another search
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Name | Age | Since | Title |
---|---|---|---|
David Putrino | - | - | Member of Medical Advisory Board |
Jennifer Morgan | - | - | Member of Medical Advisory Board |
Henry William Bosch | - | - | Member of Medical Advisory Board |
Mohit Kaushal | 44 | 2023 | Non-Executive Director |
Nik Zeps | - | - | Member of Medical Advisory Board |
Philip Finch | - | - | Member of Medical Advisory Board |
Richard Magtengaard | - | 2021 | Member of Medical Advisory Board |
John Edward Tooke | 74 | 2020 | Member of Medical Advisory Board & Independent Non-Executive Director |
Alistair Vickery | - | 2019 | Executive Medical Director & Director |
Michael Winlo | - | 2019 | MD & Director |
Karen L. Smith | 55 | 2021 | Non-Executive Director & Chairman of Strategic Advisory Board |
Greg Hutchinson | - | 2023 | Independent Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review